CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
2018; Cell Press; Volume: 34; Issue: 1 Linguagem: Inglês
10.1016/j.ccell.2018.03.023
ISSN1878-3686
AutoresMary E. Klein, Marta Kovatcheva, Lara E. Davis, William D. Tap, Andrew Koff,
Tópico(s)Cancer-related cognitive impairment studies
ResumoCDK4/6 inhibitors are among a new generation of therapeutics. Building upon the striking success of the combination of CDK4/6 inhibitors and the hormone receptor antagonist letrozole in breast cancer, many other combinations have recently entered clinical trials in multiple diseases. To achieve maximal benefit with CDK4/6 inhibitors it will be critical to understand the cellular mechanisms by which they act. Here we highlight the mechanisms by which CDK4/6 inhibitors can exert their anti-tumor activities beyond simply enforcing cytostatic growth arrest, and discuss how this knowledge may inform new combinations, improve outcomes, and modify dosing schedules in the future.
Referência(s)